LEARN MORE ABOUT CUROSURF® (poractant alfa)
The resources below offer detailed information on the use of CUROSURF, including educational videos and clinical data.
NICU Resources
Educational Videos
CUROSURF User Guide Video
The User Guide Video details the safety and efficacy data behind CUROSURF, and walks through the storage, dosing and administration procedures found in our Full Prescribing Information. This video may be particularly helpful during a Skills Day or for educating new staff.
The User Guide Video details the safety and efficacy data behind CUROSURF, and walks through the storage, dosing and administration procedures found in our Full Prescribing Information. This video may be particularly helpful during a Skills Day or for educating new staff.
INSURE: An Option for Treating Infants Following NIV Failure
This short video provides an overview of some of the research behind the INSURE Strategy and a detailed step-by-step video guide of how to administer CUROSURF.
This short video provides an overview of some of the research behind the INSURE Strategy and a detailed step-by-step video guide of how to administer CUROSURF.
Pharmacy Resources
Evaluating Surfactants for Formulary
Since surfactants cannot be considered pharmaceutical equivalents, it is important to evaluate the drug class comprehensively. This white paper discusses some factors to consider and which stakeholders to consult as you evaluate the surfactant class.
Since surfactants cannot be considered pharmaceutical equivalents, it is important to evaluate the drug class comprehensively. This white paper discusses some factors to consider and which stakeholders to consult as you evaluate the surfactant class.
We worked with Carla Christensen, PharmD to develop this video presentation of some of the considerations that she recommends incorporating into a surfactant Medication Use Evaluation.
Video Lectures
The INSURE Strategy: Selective Surfactant Following nCPAP Failure
In this lecture, Dana Evans, MHA, RRT-NPS, highlights some of the latest research into less invasive ventilation for babies with respiratory distress syndrome, and how CUROSURF® (poractant alfa) may be a good fit for your protocols.
In this lecture, Dana Evans, MHA, RRT-NPS, highlights some of the latest research into less invasive ventilation for babies with respiratory distress syndrome, and how CUROSURF® (poractant alfa) may be a good fit for your protocols.
A Comparison of Approved Natural Surfactants
In this “grand rounds style” lecture, Lance Parton, MD, FAAP, presents some of the similarities and differences between the currently available natural exogenous surfactants.
In this “grand rounds style” lecture, Lance Parton, MD, FAAP, presents some of the similarities and differences between the currently available natural exogenous surfactants.
Evaluating Surfactants: A Pharmacy Perspective
Presented by Jennifer Gorrell, PharmD, this “grand rounds style” presentation includes some information about surfactants that might be helpful to consider from a pharmacy perspective.
Presented by Jennifer Gorrell, PharmD, this “grand rounds style” presentation includes some information about surfactants that might be helpful to consider from a pharmacy perspective.
Clinical Studies
Click on the image or title to download each PDF. Please note that, due to licensing arrangements with publishers, some downloads are being provided directly from the publisher’s website.
Click on the image or title to download each PDF. Please note that, due to licensing arrangements with publishers, some downloads are being provided directly from the publisher’s website.
Less Invasive Ventilation
Infants with RDS may vary markedly in the severity of respiratory disease maturity and presence of other complications, which makes it necessary to individualize patient care. Infants receiving CUROSURF should get frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified in response to respiratory changes, because the administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung compliance.
Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks’ gestation
Verder H, Albertsen P, Ebbesen F, et al. Pediatrics. 1999;103:1-6.
This was a multicenter, randomized controlled trial and was one of the first to demonstrate the efficacy of CUROSURF when used in conjunction with nCPAP and the INSURE strategy.
Verder H, Albertsen P, Ebbesen F, et al. Pediatrics. 1999;103:1-6.
This was a multicenter, randomized controlled trial and was one of the first to demonstrate the efficacy of CUROSURF when used in conjunction with nCPAP and the INSURE strategy.
Early extubation and nasal continuous positive airway pressure after surfactant treatment for respiratory distress syndrome among preterm infants <30 weeks’ gestation
Dani C, Bertini G, Pezzati M, Cecchi A, Caviglioli C, Rubaltelli FF. Pediatrics. 2004;113:e560-e563.
This prospective, randomized clinical trial further explores the efficacy of CUROSURF with the INSURE strategy.
Dani C, Bertini G, Pezzati M, Cecchi A, Caviglioli C, Rubaltelli FF. Pediatrics. 2004;113:e560-e563.
This prospective, randomized clinical trial further explores the efficacy of CUROSURF with the INSURE strategy.
Continuous positive airway pressure failure in preterm infants: incidence, predictors and consequences
Dargaville PA, Aiyappan A, De Paoli AG, et al. Neonatology. 2013;104(1):8-14.
This retrospective analysis of prospectively collected data led to the conclusion that although there was no perfect indicator of nCPAP failure, it was predicted by high FiO2 (above 0.30) in the first hours of life. This study may be relevant as clinicians consider which patients are candidates for selective surfactant with INSURE.
Dargaville PA, Aiyappan A, De Paoli AG, et al. Neonatology. 2013;104(1):8-14.
This retrospective analysis of prospectively collected data led to the conclusion that although there was no perfect indicator of nCPAP failure, it was predicted by high FiO2 (above 0.30) in the first hours of life. This study may be relevant as clinicians consider which patients are candidates for selective surfactant with INSURE.
Comparative Trials
A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants
Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K; and The North American Study Group. American Journal of Perinatology. 2004;21:109-119.
This study found that the higher 200 mg/kg dose of CUROSURF resulted in faster onset of action and decreased FiO2 requirements compared to a 100 mg/kg dose of Survanta.*
Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K; and The North American Study Group. American Journal of Perinatology. 2004;21:109-119.
This study found that the higher 200 mg/kg dose of CUROSURF resulted in faster onset of action and decreased FiO2 requirements compared to a 100 mg/kg dose of Survanta.*
Dosing of porcine surfactant: effect on kinetics and gas exchange in respiratory distress syndrome
Cogo PE, Facco M, Simonato M, et al. Pediatrics. 2009;124(5):e950-e957.
This pharmacokinetic study using CUROSURF with a small amount of radiolabeled dipalmitoylphosphatidylcholine (DPPC) added found that compared with a 100 mg/kg dose of Survanta, the 200 mg/kg dose of CUROSURF demonstrated a longer DSPC half life.*
Cogo PE, Facco M, Simonato M, et al. Pediatrics. 2009;124(5):e950-e957.
This pharmacokinetic study using CUROSURF with a small amount of radiolabeled dipalmitoylphosphatidylcholine (DPPC) added found that compared with a 100 mg/kg dose of Survanta, the 200 mg/kg dose of CUROSURF demonstrated a longer DSPC half life.*
A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome
Malloy CA, Nicoski P, Muraskas JK. Acta Paediatrica. 2005;94:779-784.
This prospective, randomized clinical trial found that infants who received CUROSURF had a lower FiO2 requirement in the first 48 hours after surfactant therapy compared to infants who received beractant.*
Malloy CA, Nicoski P, Muraskas JK. Acta Paediatrica. 2005;94:779-784.
This prospective, randomized clinical trial found that infants who received CUROSURF had a lower FiO2 requirement in the first 48 hours after surfactant therapy compared to infants who received beractant.*
*Physiological and pharmacokinetic end points (eg, faster reduction in FiO2, lower respiratory support and longer DSPC half-life) have not been proven to impact key clinical outcomes such as mortality due to respiratory distress syndrome (RDS).
An open label comparison of calfactant and poractant alfa administration traits and impact on neonatal intensive care unit resources
Gerdes JS, Seiberlich W, Sivieri EM, et al. Journal of Pediatric Pharmacology and Therapeutics. 2006;11:92-100.
This study compared administration characteristics including administration time, patient recovery time, reflux and bradycardia.
Gerdes JS, Seiberlich W, Sivieri EM, et al. Journal of Pediatric Pharmacology and Therapeutics. 2006;11:92-100.
This study compared administration characteristics including administration time, patient recovery time, reflux and bradycardia.
Administration traits or endpoints (eg, faster reduction in FiO2, reflux or bradycardia rates, or oxygen desaturation) have not been proven to impact key clinical outcomes such as mortality or BPD due to RDS.